Study of ANG1005 for Recurrent High-Grade Glioma
Author Information
Author(s): Dmello Crismita, Brenner Andrew, Piccioni David, Wen Patrick Y, Drappatz Jan, Mrugala Maciej, Lewis Lionel D, Schiff David, Fadul Camilo E, Chamberlain Marc, Kesari Santosh, Ahluwalia Manmeet, Ghosh Debora, Sonabend Adam M, Kumthekar Priya
Primary Institution: Northwestern Medicine Malnati Brain Tumor Institute of the Lurie Comprehensive Cancer Center, Feinberg School of Medicine, Chicago, Illinois, USA
Hypothesis
The study aims to evaluate the efficacy, safety, and tolerability of ANG1005 in patients with recurrent high-grade glioma.
Conclusion
ANG1005 was found to be safe in patients with recurrent high-grade glioma, but the primary efficacy endpoint was not met.
Supporting Evidence
- ANG1005 was shown to be safe in patients with recurrent high-grade glioma.
- The primary efficacy endpoints of objective response rate and progression-free survival were not met.
- The most common adverse events included hematologic issues, alopecia, and fatigue.
- Median overall survival varied across treatment arms, with the highest in Arm 3.
Takeaway
This study tested a new drug called ANG1005 to see if it helps people with a serious brain tumor, but it didn't work as well as hoped.
Methodology
A phase II, multicenter, open-label study with 73 patients divided into three treatment arms based on their tumor type.
Potential Biases
Patients were heavily pretreated, which may affect the efficacy results.
Limitations
The results are preliminary due to the small number of subjects and the non-contemporary nature of tumor classification.
Participant Demographics
Median age was 51 years, with 63% male participants.
Statistical Information
Confidence Interval
95% CI: 1.4, 2.1 for median PFS; 95% CI: 3.4, 14.6 for median OS in Arm 1.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website